The Specialist Forum Volume 13 No 11 November 2013 | Page 85
Zuvamor
®
March 2013
Dear Healthcare Provider,
AstraZeneca Pharmaceuticals and Aspen are pleased to announce the launch of Zuvamor® (rosuvastatin), making the
original rosuvastatin more accessible to patients.
Zuvamor® is indicated for patients with primary hypercholesterolaemia, mixed dyslipidaemia and isolated
hypertriglyceridaemia or familial hypercholesterolaemia, either alone or as an adjunct to diet and other lipid
lowering treatments. 1
Please see below for prices approved by the Department of Health:
Nappi code
Product Name
Active
Ingredient
Strength
Pack Size
Dosage Form
NEW SEP
(ex VAT)
717520001
Zuvamor® 10
Rosuvastatin
10 mg
28
Tabs
R 138.41
717521001
Zuvamor® 20
Rosuvastatin
20 mg
28
Tabs
R 200.35
717522001
Zuvamor® 40
Rosuvastatin
40 mg
28
Tabs
R 243.51
Should you require more information, please contact Claude Hadebe (011) 239-3412 or our Medical Hotline on
Should you require more information, please contact Lindi Kekana on on (011) 239-3480 or our MedicalHotline on
0800 118 088.
0800118 088.
Kind Regards,
Kind Regards,
Lindi Kekana
Claude Hadebe
Saras Rosin
Senior Marketing Business Development
AstraZeneca Pharmaceuticals
Head of Marketing: Pharma
Commercial Manager:
Aspen Pharmacare
Cardiovascular Portfolio Marketing
Aspen Pharmacare
Reference: 1. Zuvamor® approved package insert.
S4 Zuvamor® 10. Reg. No: 36/7.5/0353; Zuvamor® 20. Reg. No: 36/7.5/0354; Zuvamor® 40. Reg. No: 36/7.5/0355. Each tablet contains 10 mg, 20 mg or 40 mg of rosuvastatin respectively as rosuvastatin
calcium. For further details please refer to the package insert approved by the medicines regulatory authority. Applicant: AstraZeneca Pharmaceuticals (Pty) Limited. Co. Reg. No./Nr. 1992/005854/07,
5 Leeuwkop Road, Sunninghill, 2157. Marketed by: Aspen Pharmacare. Building 12, Healthcare Park, Woodlands Drive, Woodmead, 2191. Medical Information Hotline 0800 118 088.
A 16079 03/13. ZUM 03/13/002.
Page 26
July 2013 | The Specialist Forum